AHK-Cu: The Copper Tripeptide Studied for Hair Growth
Copper Peptides in Skincare
10⁻¹² M
Picomolar concentrations of AHK-Cu stimulated human hair follicle elongation in the only published study on this peptide, suggesting activity at extremely low doses.
Pyo et al., Archives of Pharmacal Research, 2007
Pyo et al., Archives of Pharmacal Research, 2007
View as imageAHK-Cu is a synthetic copper-binding tripeptide composed of alanine, histidine, and lysine complexed with a copper(II) ion. A single published study from 2007 demonstrated that this peptide stimulated human hair follicle elongation and dermal papilla cell proliferation at picomolar to nanomolar concentrations (Pyo et al., Archives of Pharmacal Research, 2007, PMID 17703734). That finding generated interest in AHK-Cu as a potential hair growth ingredient, but the evidence base remains extremely thin: one in vitro study, no human clinical trials, and no regulatory approval for any indication. For a broader overview of how copper peptides work in skincare, see the pillar article on copper peptides.
Key Takeaways
- AHK-Cu stimulated human hair follicle elongation at concentrations as low as 10⁻¹² M (picomolar) in the only published study (Pyo et al., 2007)
- The same study found AHK-Cu increased dermal papilla cell proliferation and elevated the anti-apoptotic Bcl-2/Bax ratio, suggesting follicle cell survival benefits
- AHK-Cu increased vascular endothelial growth factor (VEGF) production while decreasing transforming growth factor beta-1 (TGF-beta1) in dermal fibroblasts
- Unlike GHK-Cu, which is naturally present in human plasma, AHK-Cu is entirely synthetic with no known endogenous role
- No human clinical trials have tested AHK-Cu for hair loss, and no peer-reviewed study has replicated the 2007 findings
- The cosmetic industry has adopted AHK-Cu faster than the science supports, with products marketed before clinical validation exists
What Is AHK-Cu?
AHK-Cu consists of three amino acids in sequence: alanine (A), histidine (H), and lysine (K), chelated with a copper(II) ion. The histidine and lysine residues provide the copper-binding site through their imidazole and amino groups, forming a stable metal-peptide complex. This is the same basic copper-binding chemistry that underlies the better-studied GHK-Cu peptide, which uses glycine, histidine, and lysine.
The structural difference is a single amino acid substitution: alanine in AHK-Cu replaces glycine in GHK-Cu. This change alters the peptide's three-dimensional conformation, receptor interactions, and potentially its biological activity profile. Both peptides deliver copper to cells, but their signaling effects may differ.
AHK-Cu is also referred to as copper tripeptide-3 in cosmetic ingredient databases. It has no known endogenous function in human biology. Unlike GHK, which was first isolated from human plasma in 1973 and exists naturally at concentrations around 200 ng/mL in young adults, AHK-Cu was designed as a synthetic analog specifically to explore structure-activity relationships in copper peptide biology.[1]
The 2007 Pyo Study: The Entire Evidence Base
Nearly everything claimed about AHK-Cu for hair growth traces back to a single publication: Pyo et al., "The effect of tripeptide-copper complex on human hair growth in vitro," published in Archives of Pharmacal Research in 2007 (PMID 17703734).
What the study found
The researchers tested AHK-Cu on human hair follicles maintained in organ culture and on cultured human dermal papilla cells (DPCs). Key findings:
Hair follicle elongation. AHK-Cu at concentrations of 10⁻¹² to 10⁻⁹ M (picomolar to nanomolar range) stimulated the elongation of human hair follicles ex vivo. This is a remarkably low effective concentration, suggesting high potency at the follicle level.
Dermal papilla cell proliferation. AHK-Cu promoted the proliferation of human DPCs, the specialized mesenchymal cells at the base of the hair follicle that regulate hair cycling. DPCs are the command center of hair growth; when they shrink or lose function, hair miniaturizes and eventually stops growing.
Anti-apoptotic signaling. The ratio of Bcl-2 (anti-apoptotic) to Bax (pro-apoptotic) protein expression was elevated by AHK-Cu treatment. Levels of cleaved caspase-3 and cleaved PARP, markers of active cell death, were reduced. This indicates AHK-Cu protected DPCs from programmed cell death.
Growth factor modulation. AHK-Cu increased VEGF production by dermal fibroblasts, which could improve blood supply to hair follicles. It simultaneously decreased TGF-beta1 secretion. TGF-beta1 is a catagen-inducing factor that signals hair follicles to stop growing, so reducing it could theoretically extend the growth (anagen) phase.
What the study did not show
The study was conducted entirely in vitro and ex vivo. No living person received AHK-Cu. The hair follicles were maintained in culture dishes, not attached to a scalp with its blood supply, immune system, and hormonal environment. The study did not test whether AHK-Cu penetrates skin, reaches follicles when applied topically, or produces any visible change in hair density, thickness, or growth rate in humans.
No independent laboratory has published a replication of these findings in the 19 years since the original publication. A single unreplicated in vitro study, regardless of how compelling its results, does not constitute strong evidence for clinical effectiveness.
How AHK-Cu Compares to GHK-Cu
The comparison between AHK-Cu and GHK-Cu is inevitable because they share a copper-binding tripeptide scaffold. The differences matter.[1]
| Property | GHK-Cu | AHK-Cu |
|---|---|---|
| Sequence | Glycine-Histidine-Lysine | Alanine-Histidine-Lysine |
| Origin | Natural (human plasma) | Synthetic |
| Discovery | 1973 (Pickart) | Studied 2007 (Pyo et al.) |
| Published studies | Hundreds | One |
| Human clinical data | Yes (skin, wound healing) | None |
| Hair-specific evidence | Indirect (follicle size increase noted in reviews) | One in vitro study |
| FDA/regulatory status | Cosmetic ingredient | Cosmetic ingredient |
GHK-Cu has a deep evidence base spanning decades. Pickart's comprehensive reviews document its effects on collagen synthesis, wound healing, gene expression (modulating over 4,000 genes), and tissue remodeling.[2] Clinical studies in humans have shown that topical GHK-Cu improves skin density, reduces wrinkles, and outperforms vitamin C and retinoic acid for collagen stimulation.[3] GHK-Cu's effects on hair follicle size were noted in early reviews as part of its broader tissue remodeling profile, though dedicated hair growth trials are also lacking.
AHK-Cu's advantage, if the 2007 data hold up, is that it may have more targeted activity on hair follicle biology. The VEGF upregulation and TGF-beta1 suppression profile is specifically relevant to hair cycling. But this claim rests on a single study versus GHK-Cu's extensive publication record.
The Mechanism: Why Copper Matters for Hair
Copper plays several documented roles in hair follicle biology, independent of which peptide delivers it.
Lysyl oxidase activation. Copper is a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin in the extracellular matrix surrounding hair follicles. This structural support is essential for follicle integrity and anchoring.
Superoxide dismutase. Copper-zinc superoxide dismutase (Cu/Zn-SOD) is a critical antioxidant enzyme that protects follicular cells from oxidative damage. Oxidative stress has been directly linked to hair cycle disruption: chronic psychological stress in mice prolongs the telogen (resting) phase through increased reactive oxygen species and substance P signaling.[4]
Angiogenesis. Copper ions stimulate angiogenesis, the formation of new blood vessels. Hair follicles are among the most metabolically active structures in the body and require robust blood supply. The VEGF increase observed with AHK-Cu is consistent with copper's known pro-angiogenic effects.
Melanogenesis. Copper is essential for tyrosinase, the rate-limiting enzyme in melanin synthesis. This is why copper peptides can affect hair pigmentation as well as growth.
These copper-dependent functions apply to both GHK-Cu and AHK-Cu. The question is whether the peptide component of AHK-Cu provides additional signaling benefits beyond simple copper delivery. The Pyo 2007 data suggest it does, but without mechanistic studies comparing AHK-Cu to free copper ions or other copper carriers, the relative contribution of the peptide scaffold versus the copper itself remains unclear.
The Delivery Problem
Even if AHK-Cu stimulates hair follicles in a culture dish, getting it to those follicles through intact scalp skin is a separate challenge. Copper peptides are hydrophilic molecules that do not readily cross the stratum corneum, the skin's outermost barrier.
Research on GHK-Cu delivery demonstrated this problem directly: microneedle pretreatment of human skin enabled 134 nanomoles of GHK-Cu peptide to permeate through skin in 9 hours, compared to essentially zero through intact skin.[5] This finding has significant implications for all topical copper peptide products, including AHK-Cu serums and solutions. Without enhanced delivery methods, the peptide may not reach follicular targets in meaningful quantities.
Some approaches being explored for improved peptide delivery to hair follicles include microneedle patches, liposomal encapsulation, and nanoparticle carriers.[6] A 2026 study demonstrated that peptide-based nanocomplexes could deliver finasteride topically at 40-fold lower doses than oral administration while matching minoxidil efficacy for hair regrowth in mice.[7] These delivery advances could eventually benefit AHK-Cu formulations, but no published study has tested enhanced delivery of AHK-Cu specifically.
Other Peptides Studied for Hair Growth
AHK-Cu exists within a broader landscape of peptides being researched for hair loss. Understanding the competitive evidence landscape provides context for AHK-Cu's relative position.
Thymosin beta-4. Both endogenous and exogenous thymosin beta-4 activate hair follicle cycling by promoting stem cell migration and differentiation. Animal studies in mice and cashmere goats have shown increased hair growth rate and follicle number.[8] The evidence base is broader than AHK-Cu's but still lacks human clinical trials.
Collagen peptides. Low molecular weight collagen peptides from fish promoted hair growth across multiple experimental models by activating the Wnt/beta-catenin signaling pathway, including oral administration in mice.[9] The oral route is a practical advantage over topical peptide delivery.
GHK-Cu. As discussed above, GHK-Cu has broader evidence for skin regeneration but lacks dedicated hair growth trials. Pickart's reviews note increased hair follicle size as part of GHK-Cu's general tissue remodeling effects.[1]
None of these peptides have been tested head-to-head against minoxidil or finasteride in randomized human trials. The entire field of peptide-based hair growth remains preclinical relative to the established pharmacological options.
The Commercial Reality
AHK-Cu appears in a growing number of hair growth serums, scalp treatments, and cosmeceutical products. Marketing claims frequently reference the Pyo 2007 study without acknowledging its limitations. Phrases like "clinically proven" or "scientifically validated" appear in product copy that is supported by a single unreplicated in vitro experiment.
This gap between marketing and evidence is not unique to AHK-Cu. It reflects a broader pattern in the cosmeceutical industry where in vitro findings are extrapolated directly to product efficacy claims. The peptide itself may have genuine biological activity, but purchasing a topical product containing AHK-Cu is not equivalent to participating in the conditions of the Pyo 2007 experiment.
Concentration matters. The effective concentrations in the Pyo study were picomolar to nanomolar. Most commercial products do not disclose the concentration of AHK-Cu in their formulations, making it impossible for consumers to determine whether the product delivers a biologically relevant dose. The copper peptide antioxidant properties and collagen stimulation mechanisms relevant to the broader copper peptide class may still provide some benefit even if the hair-specific claims are unsubstantiated.
What Would Stronger Evidence Look Like?
For AHK-Cu to move from "interesting in vitro finding" to "evidence-based hair growth treatment," the following studies would be needed:
- Independent replication of the Pyo 2007 findings by a different laboratory
- Dose-response studies comparing AHK-Cu to free copper, GHK-Cu, and vehicle controls
- Skin penetration studies measuring whether topical AHK-Cu reaches the dermal papilla at active concentrations
- Animal hair growth models (e.g., C57BL/6 mouse telogen-to-anagen conversion) comparing AHK-Cu to minoxidil
- Randomized, double-blind, placebo-controlled human trial measuring hair count, hair diameter, and growth rate over at least 6 months
Until at least steps 1 through 4 are completed, claims about AHK-Cu's effectiveness for human hair loss remain speculative extrapolations from a single laboratory experiment.
The Bottom Line
AHK-Cu is a synthetic copper tripeptide with one published in vitro study showing hair follicle elongation and dermal papilla cell proliferation at very low concentrations. The mechanism is plausible: VEGF upregulation, TGF-beta1 suppression, and anti-apoptotic signaling are all relevant to hair biology. But one unreplicated study with no human data is not enough to support the clinical claims being made in the marketplace. The broader copper peptide field, anchored by decades of GHK-Cu research, provides context that makes AHK-Cu's mechanism reasonable but its specific efficacy unproven.